Table 1.
Comparison of the demographic and laboratory data between nephrotic patients with prednisolone therapy and nephritic patients without prednisolone therapy
| Nephrotic patients with prednisolone therapy n= 60 | Nephritic patients without prednisolone therapy n= 30 | P value | |
|---|---|---|---|
| Age (years) | 50 ± 20 | 50 ± 20 | 0.958 |
| Sex (M/F) | 33/27 | 17/13 | 1.000 |
| Smoking +/− | 3/57 | 2/28 | 1.000 |
| Alcohol +/− | 1/59 | 1/29 | 1.000 |
| Tea +/− | 6/54 | 2/28 | 0.714 |
| Coffee +/− | 1/59 | 0/30 | 1.000 |
| Past PUD history +/− | 2/58 | 1/29 | 1.000 |
| Hp infection +/− | 20/40 | 11/19 | 0.816 |
| Serum albumin (g dl−1) | 2.3 ± 0.2 | 3.2 ± 0.5 | <0.001 |
| Serum creatinine (mg dl−1) | 1.3 ± 0.7 | 1.3 ± 0.6 | 0.785 |
| Endoscopic peptic ulcers | 1/59 | 1/29 | 1.000 |
| Ulcer complications | 0/60 | 0/30 | |
| Pre-therapy data | |||
| Gastric pH | 2.8 ± 1.4 | 2.6 ± 1.2 | 0.430 |
| Serum TXB2 (pg ml−1) (COX-1 activity) | 6360 ± 910 | 6510 ± 710 | 0.418 |
| Serum PGE2 (pg ml−1) (COX-2 activity) | 855 ± 170 | 853 ± 170 | 0.967 |
| Gastric TXB2 (ng mg−1 protein) | 4214 ± 1478 | 4426 ± 1293 | 0.428 |
| Gastric PGE2 (ng mg−1 protein) | 1505 ± 795 | 1370 ± 590 | 0.414 |
| Post-therapy data | n= 58 | n= 30 | |
| Gastric pH | 2.9 ± 1.5 | 2.7 ± 1.2 | 0.374 |
| Serum TXB2 (pg ml−1) (COX-1 activity) | 6340 ± 710 | 6400 ± 950 | 0.780 |
| Serum PGE2 (pg ml−1) (COX-2 activity) | 887 ± 220 | 885 ± 188 | 0.968 |
| Gastric TXB2 (ng mg−1 protein) | 3973 ± 1360 | 4210 ± 1153 | 0.432 |
| Gastric PGE2 (ng mg−1 protein) | 939 ± 730 | 1333 ± 576 | 0.012 |
PUD, peptic ulcer disease, Hp, Helicobacter pylori; TX, thromboxane, PG, prostaglandin.